Kits and methods to distinguish false labor and true labor
Kits and methods to distinguish between false and true labor are provided. The kits and methods can utilize differences in abundance and/or differences in the rate of change in abundance of B7-H2, SORC2, TF, C1-Esterase Inhibitor, Ran, IMDH1 and/or PGAM1, as markers of true labor.
1. A kit comprising: an array that measures tissue factor (TF) in combination with Ras-related Nuclear protein (Ran), Inosine-5′-monophosphate dehydrogenase (IMDH1), and Phosphoglycerate mutase 1 (PGAM1), from a sample obtained from a pregnant female.
2. The kit of claim 1 comprising instructions that direct calculation of changes in abundance (CA) of TF, Ran, IMDH1, and PGAM1 as compared to a reference level calculated from samples derived from a reference population, at a time when members of said reference population were not in true labor.
3. The kit of claim 2 comprising instructions that direct calculation of a true labor score using change of abundance of true labor markers, wherein CA TF , CA Ran , CA IMDH1 , and CA PGAM1 are used in a Linear Discriminant Analysis Model.
4. The kit of claim 3 comprising instructions that direct analysis of the true labor score;
wherein the true labor score comprises two threshold values, X and Y,
wherein a true labor score≤X denotes that the pregnant female is in false labor, and
wherein a true labor score>Y denotes that the pregnant female is in true labor.
5. The kit of claim 1 , comprising instructions that direct sample collection be obtained from a pregnant female between 33 and 40 weeks of the female's pregnancy.
6. The kit of claim 1 , comprising instructions to collect a plasma or serum sample.
7. The kit of claim 1 , comprising instructions to collect the sample when the pregnant female is experiencing symptoms associated with false labor and true labor, wherein the symptoms optionally are contractions.
8. The kit of claim 1 , wherein the array comprises one or more well(s) coated with:
anti-TF antibodies; and/or
anti-Ran antibodies; and/or
anti-IMDH1 antibodies; and/or
anti-PGAM1 antibodies.